title: Schneiderian first-rank symptoms associated with fluvoxamine treatment: a case report.
abstract: This communication describes a patient who developed Schneiderian first-rank symptoms in the course of treatment with fluvoxamine. The patient, a 28-year-old man suffering from panic disorder, developed several first-rank symptoms during fluvoxamine administration. These symptoms abated 1 week after fluvoxamine treatment was discontinued and haloperidol was started. Although haloperidol was discontinued, no further hallucinations or delusions occurred. This finding suggests that fluvoxamine can precipitate Schneiderian first-rank symptoms in some susceptible patients.
authors.affiliation: Department of Psychiatry, School of Medicine, University of Occupational and Environmental Health 1-1 Iseigaoka, Yahatanisi-ku, Kitakyusyu 807-8555, Japan. EZD04735@nifty.com
authors.forename: Nobuhisa
authors.initials: N
authors.lastname: Ueda
authors.forename: Takeshi
authors.initials: T
authors.lastname: Terao
authors.forename: Osamu
authors.initials: O
authors.lastname: Ohmori
authors.forename: Jun
authors.initials: J
authors.lastname: Nakamura
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D003702:Delusions / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D003937:Diagnosis, Differential; D016666:Fluvoxamine / Q000009:adverse effects* / Q000627:therapeutic use; D006212:Hallucinations / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D008297:Male; D016584:Panic Disorder / Q000188:drug therapy* / Q000523:psychology; D016896:Treatment Outcome
chemical_list: D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D006220:Haloperidol; D016666:Fluvoxamine